Переходьте в офлайн за допомогою програми Player FM !
Updates in immunotherapy for skin cancer
Manage episode 408280508 series 2424442
In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.
We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.
If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.
Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.
The post Updates in immunotherapy for skin cancer appeared first on VJOncology.
174 епізодів
Manage episode 408280508 series 2424442
In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.
We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.
If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.
Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.
The post Updates in immunotherapy for skin cancer appeared first on VJOncology.
174 епізодів
Усі епізоди
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.